tallózása szerző szerint "Klikovits T"

A találatok rendezése: Rendezés: Találatok:

  • Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma 
    Klikovits T; Stockhammer P; Laszlo V; Dong Y; Hoda MA; Ghanim B; Opitz I; Frauenfelder T; Nguyen-Kim TDL; Weder W; Berger W; Grusch M; Aigner C; Klepetko W; Döme, Balázs; Rényi-Vámos, Ferenc István; Oehler R; Hegedűs, Balázs (2017)
    Only limited information is available on the role of complement activation in malignant pleural mesothelioma (MPM). Thus, we investigated the circulating and tissue levels of the complement component 4d (C4d) in MPM. Plasma ...
  • Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma. 
    Ghanim B; Hoda MA; Klikovits T; Winter MP; Alimohammadi A; Grusch M; Döme Balázs; Arns B; Schenk P; Jakopovic M; Samarzija M; Brcic L; Filipits M; Laszlo Viktoria; Klepetko W; Berger W; Hegedüs Balázs (2014)
    Background:To investigate the clinical utility of pretreatment plasma fibrinogen levels in malignant pleural mesothelioma (MPM) patients.Methods:A retrospective multicenter study was performed in histologically proven MPM ...
  • Epigenetic down-regulation of integrin alpha7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma 
    Laszlo V; Hoda MA; Garay, Tamás; Pirker C; Ghanim B; Klikovits T; Dong YW; Rózsás, Anita; Kenessey, István; Szirtes, Ildikó; Grusch M; Jakopovic M; Samarzija M; Brcic L; Kern I; Rozman A; Popper H; Zochbauer-Muller S; Heller G; Altenberger C; Ziegler B; Klepetko W; Berger W; Döme, Balázs; Hegedűs, Balázs (2015)
    Malignant pleural mesothelioma (MPM) is a devastating malignancy characterized by invasive growth and rapid recurrence. The identification and inhibition of molecular components leading to this migratory and invasive ...
  • Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy 
    Schelch K; Hoda MA; Klikovits T; Munzker J; Ghanim B; Wagner C; Garay, Tamás; Laszlo, Viktoria; Setinek U; Döme, Balázs; Filipits M; Pirker C; Heffeter P; Selzer E; Tóvári, József; Török, Szilvia; Kenessey, István; Holzmann K; Grasl-Kraupp B; Marian B; Klepetko W; Berger W; Hegedűs, Balázs; Grusch M (2014)
    RATIONALE: Malignant pleural mesothelioma is an aggressive malignancy characterized by frequent resistance to chemo- and radiotherapy, poor outcome, and limited therapeutic options. Fibroblast growth factors (FGFs) and ...
  • Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis 
    Kirschner MB; Pulford E; Hoda MA; Rózsás, Anita; Griggs K; Cheng YY; Edelman JJ; Kao SC; Hyland R; Dong Y; Laszlo V; Klikovits T; Vallely MP; Grusch M; Hegedűs, Balázs; Döme, Balázs; Klepetko W; van Zandwijk N; Klebe S; Reid G (2015)
    BACKGROUND: Fibulin-3 (FBLN3) was recently presented as a promising novel biomarker for malignant pleural mesothelioma (MPM), warranting independent validation studies. METHODS: ELISA was used to measure cellular and ...
  • Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study 
    Ghanim B; Klikovits T; Hoda MA; Lang, György; Szirtes, Ildikó; Setinek U; Rozsas A; Rényi-Vámos, Ferenc István; Laszlo V; Grusch M; Filipits M; Scheed A; Jakopovic M; Samarzija M; Brcic L; Stancic-Rokotov D; Kern I; Rozman A; Dekan G; Klepetko W; Berger W; Glasz, Tibor; Döme, Balázs; Hegedűs, Balázs (2015)
    BACKGROUND: Estimating the prognosis in malignant pleural mesothelioma (MPM) remains challenging. Thus, the prognostic relevance of Ki67 was studied in MPM. METHODS: Ki67 index was determined in a test cohort of 187 cases ...
  • Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors 
    Torok S; Rezeli M; Kelemen O; Vegvari A; Watanabe K; Sugihara Y; Tisza A; Marton T; Kovacs I; Tovari J; Laszlo V; Helbich TH; Hegedűs, Balázs; Klikovits T; Hoda MA; Klepetko W; Paku S; Marko-Varga G; Dome B (2017)
    Resistance mechanisms against antiangiogenic drugs are unclear. Here, we correlated the antitumor and antivascular properties of five different antiangiogenic receptor tyrosine kinase inhibitors (RTKIs) (motesanib, pazopanib, ...